AbbVie (ABBV) R&D In Process (2012 - 2026)
AbbVie (ABBV) reported R&D In Process of $744.0 million for Q1 2026, up 200.0% year-over-year from $248.0 million in Q1 2025, and down 41.19% on a QoQ basis from $1.3 billion in Q4 2025.
AbbVie (ABBV) has 15 years of R&D In Process data on file, last reported at $744.0 million in Q1 2026.
- Quarterly R&D In Process rose 200.0% year-over-year to $744.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.3 billion (up 115.1% YoY) and the FY2025 annual result came in at $5.0 billion, up 81.94% from the prior year.
- R&D In Process declined to $744.0 million in Q1 2026 per ABBV's latest filing, from $1.3 billion in the prior quarter.
- Across five years, R&D In Process topped out at $1.9 billion in Q3 2025 and bottomed at $40.0 million in Q3 2022.
- The 5-year median for R&D In Process is $250.0 million (2024), against an average of $462.5 million.
- The widest annual swing landed in 2022, when R&D In Process sank 90.0%; it then jumped 2217.07% in 2025.
- Tracing ABBV's R&D In Process over 5 years: stood at $243.0 million in 2022, then advanced by 16.05% to $282.0 million in 2023, then surged by 396.45% to $1.4 billion in 2024, then declined by 9.64% to $1.3 billion in 2025, then tumbled by 41.19% to $744.0 million in 2026.
- Per Business Quant, the three latest ABBV R&D In Process figures stand at $744.0 million (Q1 2026), $1.3 billion (Q4 2025), and $1.9 billion (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | 11.30 Bn |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 584.00 Mn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 744.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 107.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 137.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 94.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 744.00 Mn |
| Dec 31, 2025 | 1.27 Bn |
| Sep 30, 2025 | 1.90 Bn |
| Jun 30, 2025 | 350.00 Mn |
| Mar 31, 2025 | 248.00 Mn |
| Dec 31, 2024 | 1.40 Bn |
| Sep 30, 2024 | 82.00 Mn |
| Jun 30, 2024 | 250.00 Mn |
| Mar 31, 2024 | 164.00 Mn |
| Dec 31, 2023 | 282.00 Mn |
| Sep 30, 2023 | 66.00 Mn |
| Jun 30, 2023 | 280.00 Mn |
| Mar 31, 2023 | 150.00 Mn |
| Dec 31, 2022 | 243.00 Mn |
| Sep 30, 2022 | 40.00 Mn |
| Jun 30, 2022 | 269.00 Mn |
| Mar 31, 2022 | 130.00 Mn |
| Dec 31, 2021 | 370.00 Mn |
| Sep 30, 2021 | 400.00 Mn |
| Jun 30, 2021 | 132.00 Mn |
| Mar 31, 2021 | 185.00 Mn |
| Dec 31, 2020 | 200.00 Mn |
| Sep 30, 2020 | 45.00 Mn |
| Jun 30, 2020 | 750.00 Mn |
| Dec 31, 2019 | 139.00 Mn |
| Jun 30, 2019 | 91.00 Mn |
| Mar 31, 2019 | 155.00 Mn |
| Dec 31, 2018 | 300.00 Mn |
| Sep 30, 2018 | 55.00 Mn |
| Mar 31, 2018 | 69.00 Mn |
| Dec 31, 2017 | 312.00 Mn |
| Jun 30, 2017 | 15.00 Mn |
| Dec 31, 2016 | 40.00 Mn |
| Sep 30, 2016 | 80.00 Mn |
| Jun 30, 2016 | 70.00 Mn |
| Mar 31, 2016 | 10.00 Mn |
| Jun 30, 2015 | 23.00 Mn |
| Mar 31, 2015 | 127.00 Mn |
| Dec 31, 2014 | 28.00 Mn |
| Sep 30, 2014 | 308.00 Mn |
| Jun 30, 2014 | 16.00 Mn |
| Dec 31, 2013 | 48.00 Mn |
| Sep 30, 2013 | 45.00 Mn |
| Jun 30, 2013 | 70.00 Mn |
| Dec 31, 2012 | 28.00 Mn |
| Jun 30, 2012 | 110.00 Mn |
| Mar 31, 2012 | 150.00 Mn |